Previous 10 | Next 10 |
Webinar to be hosted on Thursday Sept. 22, 2022 at 12:00 p.m. ET, register here . Dr. Houghton will discuss challenges in drug development for pediatric cancers and preliminary results from Lantern’s drug candidates in preclinical pediatric cancer models with unmet clin...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and develop...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced ...
DALLAS, TX / ACCESSWIRE / August 19, 2022 / RedChip Companies will air a new interview on Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("ML") platform to transform the cost...
Lantern Pharma Inc. (LTRN) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margrave – Chief Financial Officer Conference Call...
The following slide deck was published by Lantern Pharma Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Lantern Pharma Inc. 2022 Q2 - Results - Earnings Call Presentation
Lantern Pharma press release ( NASDAQ: LTRN ): Q2 GAAP EPS of -$0.41 beats by $0.11 . Cash, cash equivalents, and marketable securities were approximately $62.2 million as of June 30, 2022, compared to approximately $79.6 million as of June 30, 2021. For further ...
Lantern has launched the Phase 2 clinical trial, Harmonic ™ , for LP-300. The Harmonic ™ clinical trial is focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022. The IND applications for bot...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced tha...
Codexis ( CDXS ) -23% as forecast comes below estimates . 10x Genomics ( TXG ) -19% on guiding Q2 revenues below consensus . Innovative Industrial Properties ( IIPR ) -21% . Lantern Pharma ( LTRN ) -10% . Sunrun ( RUN ) -8%...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...